In a report released today, Randall Stanicky from RBC Capital maintained a Hold rating on Perrigo Company plc (NYSE: PRGO), with a price target of $67. The company’s shares opened today at $69.01, close to its 52-week low of $67.69.
According to TipRanks.com, Stanicky ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.2% and a 32.4% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Pacira Pharmaceuticals, and Evofem Biosciences Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Perrigo Company plc with a $83.43 average price target, representing a 20.9% upside. In a report issued on July 30, Argus Research also downgraded the stock to Hold.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $95.93 and a one-year low of $67.69. Currently, Perrigo Company plc has an average volume of 1.24M.
Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRGO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Perrigo Co. Plc is a healthcare company, which engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals.
